key takeaways 0:00 The Warning Signs You Should Not Ignore 1:10 Why GLP-1 Medications Affect Skin, Hair, and Nails 2:45 The Real Problem
The Phase 2 VENTURE study, published on January 12 th (2025) in Obesity demonstrates that weekly subcutaneous VK2735 delivered rapid, dose-dependent weight loss over just 13 weeks, with efficacy that stands out even in a crowded GLP-1/GIP landscape
Together, they promote longer, more restorative sleep cycles
More than 70% of people taking the higher Wegovy dose reported issues such as nausea, vomiting or constipation
Weight loss becomes psychologically meaningful long before it becomes medically meaningful
Along side these complementary therapies we offer cutting-edge IV infusions and peptide therapy to help support the metabolic fuel pathways of the immune, muscular, and psychological networks